BMRN
Price
$56.49
Change
+$1.28 (+2.32%)
Updated
Oct 22, 03:45 PM (EDT)
Capitalization
10.69B
4 days until earnings call
Intraday BUY SELL Signals
INCY
Price
$115.89
Change
+$2.45 (+2.16%)
Updated
Oct 22, 11:12 AM (EDT)
Capitalization
22.99B
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BMRN vs INCY

BMRN vs INCY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BMRN vs. INCY commentary
Oct 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and INCY is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BMRN with price predictions
Oct 21, 2026

BMRN in downward trend: price dove below 50-day moving average on September 22, 2026

BMRN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for BMRN crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Indicator exited the oversold zone, 21 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 62 cases where BMRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on BMRN as a result. In 52 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

The Moving Average Convergence Divergence (MACD) for BMRN just turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.

Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 166 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.691) is normal, around the industry mean (2.988). BMRN's P/E Ratio (149.216) is considerably higher than the industry average of (-1.158). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for INCY with price predictions
Oct 21, 2026

INCY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 01, 2026

INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 40 cases where INCY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Oscillator exited the oversold zone, 20 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INCY as a result. In 60 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for INCY just turned positive on October 20, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in 20 of 35 cases over the following month. The odds of a continued upward trend are 57%.

Following a +3.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in 208 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

INCY moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

The Aroon Indicator for INCY entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.624) is normal, around the industry mean (2.988). P/E Ratio (13.953) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (438.009).

FUNDAMENTALS RATINGS
BMRN vs INCY: Fundamental Ratings
BMRN
INCY
OUTLOOK RATING
1..100
564
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
8933
PRICE GROWTH RATING
1..100
5845
P/E GROWTH RATING
1..100
178
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (92) in the Biotechnology industry is in the same range as BMRN (98). This means that INCY’s stock grew similarly to BMRN’s over the last 12 months.

INCY's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for BMRN (100). This means that INCY’s stock grew somewhat faster than BMRN’s over the last 12 months.

INCY's SMR Rating (33) in the Biotechnology industry is somewhat better than the same rating for BMRN (89). This means that INCY’s stock grew somewhat faster than BMRN’s over the last 12 months.

INCY's Price Growth Rating (45) in the Biotechnology industry is in the same range as BMRN (58). This means that INCY’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for INCY (78). This means that BMRN’s stock grew significantly faster than INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNINCY
RSI
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
59%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
56%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 8 days ago
59%
Bullish Trend 3 days ago
64%
Declines
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 10 days ago
55%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
65%
Aroon
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
57%
COMPARISON
Comparison
Oct 22, 2026
Stock price -- (BMRN: $55.21 vs. INCY: $113.44)
Brand notoriety: BMRN: Not notable vs. INCY: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 108% vs. INCY: 86%
Market capitalization -- BMRN: $10.69B vs. INCY: $22.99B
BMRN [@Biotechnology] is valued at $10.69B. INCY’s [@Biotechnology] market capitalization is $22.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.95B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 1 FA rating(s) are green while INCY’s FA Score has 1 green FA rating(s).

  • BMRN’s FA Score: 1 green, 4 red.
  • INCY’s FA Score: 1 green, 4 red.
According to our system of comparison, INCY is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 6 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s).

  • BMRN’s TA Score: 6 bullish, 4 bearish.
  • INCY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, BMRN is a better buy in the short-term than INCY.

Price Growth

BMRN (@Biotechnology) experienced а +0.13% price change this week, while INCY (@Biotechnology) price change was +1.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.05%. For the same industry, the average monthly price growth was -18.13%, and the average quarterly price growth was -15.34%.

Reported Earning Dates

BMRN is expected to report earnings on Oct 26, 2026.

INCY is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BMRN
Daily Signal:
Gain/Loss:
INCY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with RPRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then RPRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
-2.72%
RPRX - INCY
46%
Loosely correlated
-0.16%
HALO - INCY
43%
Loosely correlated
+0.37%
VRTX - INCY
40%
Loosely correlated
+1.92%
AXON - INCY
39%
Loosely correlated
+2.54%
BMRN - INCY
37%
Loosely correlated
-2.18%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MSTW4.670.39
+9.11%
Roundhill MSTR WeeklyPay ETF (MSTW)
SYN.X0.1833270.000884
+0.48%
Synapse cryptocurrency
TMB24.78-0.01
-0.04%
Thornburg Multi Sector Bond ETF (TMB)
FLOKI.X0.000025N/A
-0.09%
FLOKI cryptocurrency
LITZ27.98-2.11
-7.01%
Tradr 2X Short LITE Daily ETF (LITZ)